Skip to main content
Caplight Logo









Reglagene

Reglagene

Private
Houston, TexasHealthcare & Life Scienceshttps://www.reglagene.com/

Last Round

Series A

Extension

Dec 19, 2023

Est. Valuation

$25.4M

Total Funding Raised

$7.83M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Reglagene is a therapeutics company that develops brain-penetrant small-molecule medicines for the treatment of brain cancers and other neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug discoverysmall-molecule therapeuticsgene expressiontranscription factor modulationoncologybiotechnologyundruggable targetsdrug developmenttherapeutic candidatesgene regulationsmall molecule drugpreclinical researchpharma licensingbiotech pipelinedrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Reglagene Comparables

Compare Reglagene with similar companies based on industry and business-model similarity.

Reglagene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Flare Therapeutics
84%
Rgenta Therapeutics
80%
Gertrude Biomedical
79%

Reglagene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 19, 2023
Convertible DebtJun 1, 2021
Series AFeb 1, 2021
GrantMar 9, 2020
GrantDec 19, 2019
Grant
Sep 1, 2018

Reglagene Investors

Notable investors and investment history

Reglagene investors
InvestorRounds
National Cancer InstituteGrant
NIH RADxGrant
Tech Coast AngelsSeries A Extension
Viva BioInnovatorSeries A Extension
CANCER FUNDSeries A, Series A Extension
Arizona Commerce AuthorityGrant
TCA Venture GroupSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 808% MoM, from 122 to 1.1K.

  • Apr 20, 2026

    Monthly visitors grew 37% MoM.

Reglagene Filings

Explore SEC and related filing metadata, where available.

Reglagene filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Reglagene's valuation, stock price, and market status.

Is Reglagene a public or private company?

Reglagene is a private company.

What is the current stock price of Reglagene?

Reglagene is a private company with no public stock price. No recent secondary market data is available.

How much is Reglagene worth (valuation)?

Valuation information for Reglagene is not publicly available.

Can I buy Reglagene stock?

Reglagene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Reglagene's last funding round?

Reglagene's most recent funding round was Series A on December 19, 2023.

Who are the main investors in Reglagene?

Key investors in Reglagene include Desert Angels.

Will Reglagene IPO soon?

No public IPO plans have been announced for Reglagene.

How can I track Reglagene secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Reglagene's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Employee Range7
Year Founded2016
Last FundingDec 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?